GlassScriptPhysician profile
Guillermo Abesada Terk
NPI 1134313273
$10,651.09
in general payments reported to CMS, 2019-2025
59 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,708 · 2020: $1,999 · 2021: $2,503 · 2022: $1,426 · 2024: $15.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $992.94 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $757.37 | 2019-2022 | |
| Amgen INC. | $680.13 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $556.34 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $539.26 | 2019-2022 | |
| Celgene Corporation | $527.82 | 2019-2022 | |
| Incyte Corporation | $482.90 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $425.18 | 2019-2022 | |
| Pfizer INC. | $423.08 | 2019-2022 | |
| Seagen INC. | $413.63 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $399.38 | 2019-2022 | |
| Dova Pharmaceuticals | $392.09 | 2019-2021 | |
| Genzyme Corporation | $324.02 | 2019-2022 | |
| Astellas Pharma US INC | $287.38 | 2019-2022 | |
| Eisai INC. | $265.65 | 2019-2022 |
Show all 58 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guillermo Abesada Terk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.